235 related articles for article (PubMed ID: 16757911)
1. Screening for fetal chromosomal abnormalities with nuchal translucency measurement in the first trimester.
Has R; Kalelioglu I; Ermis H; Ibrahimoglu L; Yuksel A; Yildirim A; Basaran S
Fetal Diagn Ther; 2006; 21(4):355-9. PubMed ID: 16757911
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
[TBL] [Abstract][Full Text] [Related]
3. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
[TBL] [Abstract][Full Text] [Related]
4. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
5. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
[TBL] [Abstract][Full Text] [Related]
6. Prospective validation of first-trimester combined screening for trisomy 21.
Kagan KO; Etchegaray A; Zhou Y; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
[TBL] [Abstract][Full Text] [Related]
7. Comparison of first-trimester contingent screening strategies for Down syndrome.
Sahota DS; Leung TY; Chan LW; Law LW; Fung TY; Chen M; Lau TK
Ultrasound Obstet Gynecol; 2010 Mar; 35(3):286-91. PubMed ID: 20052660
[TBL] [Abstract][Full Text] [Related]
8. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia.
Zoppi MA; Ibba RM; Floris M; Monni G
Ultrasound Obstet Gynecol; 2001 Dec; 18(6):649-51. PubMed ID: 11844208
[TBL] [Abstract][Full Text] [Related]
9. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.
Bindra R; Heath V; Liao A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2002 Sep; 20(3):219-25. PubMed ID: 12230441
[TBL] [Abstract][Full Text] [Related]
10. First-trimester ultrasonographic screening for trisomy 21 using fetal nuchal translucency and nasal bone.
Sepulveda W; Wong AE; Dezerega V
Obstet Gynecol; 2007 May; 109(5):1040-5. PubMed ID: 17470580
[TBL] [Abstract][Full Text] [Related]
11. [Screening for aneuploidy by first trimester nuchal translucency measurement: results from a prospective trial including 1980 cases in a single center in Switzerland].
Tercanli S; Holzgreve W; Batukan C; Gerber A; Ermis H; Miny P
Ultraschall Med; 2002 Feb; 23(1):22-6. PubMed ID: 11842368
[TBL] [Abstract][Full Text] [Related]
12. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K; Bindra R; Cacho AM; Nicolaides KH
Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
[TBL] [Abstract][Full Text] [Related]
13. The utility of detailed first trimester ultrasound examination in abnormal fetal nuchal translucency.
Bronshtein M; Zimmer EZ; Blazer S
Prenat Diagn; 2008 Nov; 28(11):1037-41. PubMed ID: 18925580
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population.
Scott F; Peters H; Bonifacio M; McLennan A; Boogert A; Kesby G; Anderson J
Aust N Z J Obstet Gynaecol; 2004 Jun; 44(3):205-9. PubMed ID: 15191443
[TBL] [Abstract][Full Text] [Related]
15. Relation between increased fetal nuchal translucency thickness and chromosomal defects.
Kagan KO; Avgidou K; Molina FS; Gajewska K; Nicolaides KH
Obstet Gynecol; 2006 Jan; 107(1):6-10. PubMed ID: 16394033
[TBL] [Abstract][Full Text] [Related]
16. Threshold of nuchal translucency for the detection of chromosomal aberration: comparison of different cut-offs.
Kim MH; Park SH; Cho HJ; Choi JS; Kim JO; Ahn HK; Shin JS; Han JY; Kim MY; Yang JH
J Korean Med Sci; 2006 Feb; 21(1):11-4. PubMed ID: 16479057
[TBL] [Abstract][Full Text] [Related]
17. [Ultrasound screening for Down syndrome and other chromosomal abnormalities by fetal nuchal translucency measurement between 11-14 weeks of gestation].
Dimitrova V; Markov D; Chernev T; Karag'ozova Zh; Mazneĭkova V; Andonova S; Vŭzharova R
Akush Ginekol (Sofiia); 2005; 44(1):32-7. PubMed ID: 15853009
[TBL] [Abstract][Full Text] [Related]
18. Screening for trisomy 21 by fetal nuchal translucency and maternal age: a multicenter project in Germany, Austria and Switzerland.
Gasiorek-Wiens A; Tercanli S; Kozlowski P; Kossakiewicz A; Minderer S; Meyberg H; Kamin G; Germer U; Bielicki M; Hackelöer BJ; Sarlay D; Kuhn P; Klapp J; Bahlmann F; Pruggmayer M; Schneider KT; Seefried W; Fritzer E; von Kaisenberg CS;
Ultrasound Obstet Gynecol; 2001 Dec; 18(6):645-8. PubMed ID: 11844207
[TBL] [Abstract][Full Text] [Related]
19. Comparing first trimester screening performance: routine care gynaecologists' practices vs. prenatal centre.
Kozlowski P; Knippel AJ; Stressig R
Ultraschall Med; 2007 Jun; 28(3):291-5. PubMed ID: 17315110
[TBL] [Abstract][Full Text] [Related]
20. [Value of nuchal translucency thickening in the fetal chromosome abnormality screening].
Sun LJ; Wang X; Wu QQ; Ruan Y; Yao L
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):819-23. PubMed ID: 24444557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
